Physician profile
Victor H Gonzalez
NPI 1871599100
$334,730.58
in general payments reported to CMS, 2019-2025
66 companies · $18K in 2025
The $18K reported for 2025 was more than what 94% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $77K · 2020: $41K · 2021: $81K · 2022: $28K · 2023: $65K · 2024: $24K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $54K · Consulting Fee: $29K · Food and Beverage: $15K · Honoraria: $5,500 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,475 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $54,301.01 |
| Consulting Fee | $29,440.00 |
| Food and Beverage | $14,951.16 |
| Honoraria | $5,500.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,475.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $946.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $108,937.80 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $39,933.54 | 2022-2025 | Stellaris, Xipere, Stellaris Elite |
| Beaver-Visitec International, INC. | $29,080.55 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $25,442.06 | 2019-2021 | |
| Alimera Sciences, INC. | $18,230.90 | 2019-2024 | Iluvien, Yutiq |
| Regeneron Healthcare Solutions, INC. | $15,766.95 | 2020-2025 | Eylea Hd, Eylea |
| Allergan, INC. | $15,761.78 | 2019-2022 | |
| F. Hoffmann-La Roche Ag | $13,444.00 | 2019 | |
| Novartis Pharma Ag | $8,682.27 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $6,890.62 | 2022-2025 | Syfovre |
| Harrow Eye, LLC | $6,544.39 | 2023-2025 | Iheezo, Triesence |
| Lumibird Medical INC. | $6,122.02 | 2024-2025 | |
| Regeneron Pharmaceuticals, INC. | $5,287.49 | 2020-2025 | Eylea |
| Genentech USA, INC. | $4,538.22 | 2019-2025 | Vabysmo, Susvimo |
| Eyepoint US, INC. | $3,348.94 | 2019-2023 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,107.47 | 2019-2021 | |
| Alcon Vision LLC | $2,869.30 | 2019-2024 | Argos, Ngenuity, Clareon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,607.18 | 2019-2025 | |
| Cardinal Health 108 LLC | $1,790.34 | 2020-2022 | |
| Iridex Corporation | $1,750.00 | 2022 | |
| Thrombogenics, INC. | $1,681.79 | 2019 | |
| Glaukos Corporation | $1,474.42 | 2019-2024 | Idose, Istent Infinite Trabecular Micro-Bypass System Model Is3, Iaccess Precision Blade |
| Boehringer Ingelheim International Gmbh | $1,400.08 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $1,397.93 | 2019-2024 | Tecnis Simplicity, Catalys System, One Series Ultra |
| Abbvie INC. | $771.59 | 2022-2025 | |
| Astellas Pharma US INC | $725.08 | 2023-2025 | Izervay |
| Microsurgical Technology, INC. | $722.00 | 2024-2025 | |
| Eyevance Pharmaceuticals LLC | $553.15 | 2019-2022 | |
| Rxsight INC | $525.62 | 2021-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Biogen, INC. | $493.85 | 2022-2024 | Byooviz |
| Carl Zeiss Meditec, INC. | $409.45 | 2020 | |
| Mallinckrodt Hospital Products INC. | $378.49 | 2022-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $329.16 | 2025 | Purified Cortrophin Gel, Yutiq |
| Merz Pharmaceuticals, LLC | $316.71 | 2021-2023 | Xeomin |
| Topcon Healthcare, INC. | $316.69 | 2019 | |
| Biotissue Holdings INC. | $308.31 | 2019-2021 | |
| Oyster Point Pharma, INC. | $301.06 | 2023-2024 | Tyrvaya |
| Lombart Brothers, INC. | $271.70 | 2024 | Opd-III |
| Sight Sciences, INC. | $245.89 | 2021-2024 | Omni Surgical System |
| Ocular Therapeutix, INC. | $245.32 | 2023-2025 | Dextenza |
| Lilly USA, LLC | $228.32 | 2024-2025 | Mounjaro, Zepbound |
| Genentech, INC. | $189.49 | 2019-2024 | Susvimo, Vabysmo |
| Coherus Oncology, INC. | $149.45 | 2023 | |
| Tearlab Corp | $149.07 | 2023 | Tearlab Osmolarity System |
| Abbott Laboratories | $142.23 | 2021 | |
| Neurotech Pharmaceuticals, INC. | $137.39 | 2025 | |
| Kala Pharmaceuticals, INC. | $122.78 | 2021 | |
| Dompe US, INC. | $98.98 | 2024 | Oxervate |
| Aerie Pharmaceuticals, INC. | $88.89 | 2019 | |
| Optos, INC. | $76.91 | 2019 | |
| Sun Pharmaceutical Industries INC. | $64.85 | 2025 | |
| Astellas Pharma Global Development | $62.97 | 2024-2025 | Izervay |
| Heidelberg Engineering, INC. | $56.71 | 2025 | Spectralis |
| Tarsus Pharmaceuticals, INC. | $39.65 | 2024 | Xdemvy |
| Siemens Medical Solutions USA, INC. | $36.11 | 2024-2025 | Artis Icono Biplane, Magnetom Altea |
| Dutch Ophthalmic, USA | $29.89 | 2022 | |
| Oculus Surgical INC. | $21.93 | 2024 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Shire North American Group INC | $11.45 | 2019 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,857.68 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
$463,585.16 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.